Sickle Cell Diseases and Hormonal Contraception

Freie, H. M. P.

doi:10.3109/00016348309155794

Cited by 18 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These factors may lead to increased venous stasis, clotting, and pain in women with SCD receiving estrogen. 41 Regardless of these safety concerns, few studies have addressed this issue. Although the studies are small, ϳ150 individual patients may have received combined hormonal contraceptives.…”

Section: Unplanned Pregnancy and Scdmentioning

confidence: 99%

Reproductive issues in sickle cell disease

Smith‐Whitley

2014

Hematology

View full text Add to dashboard Cite

As medical advances improve survival, reduce disease-related morbidity, and improve quality of life, reproductive issues will take higher priority in the sickle cell disease (SCD) community. A wide variety of topics are addressed in this chapter, including fertility, gonadal failure, erectile dysfunction, and menstrual issues in SCD. Etiologies of impaired male fertility are multifactorial and include hypogonadism, erectile dysfunction, sperm abnormalities, and complications of medical therapies. Much less is known about the prevalence and etiology of infertility in women with SCD. Other reproductive issues in women included in this review are pain and the menstrual cycle, contraception, and preconception counseling. Finally, long-term therapies for SCD and their impact on fertility are presented. Transfusional iron overload and gonadal failure are addressed, followed by options for fertility preservation after stem cell transplantation. Focus is placed on hydroxyurea therapy given its benefits and increasing use in SCD. The impact of this agent on spermatogenesis, azoospermia, and the developing fetus is discussed. Learning Objectives• To have a better understanding of hypogonadism, sperm abnormalities, and ED in men with SCD • To recognize the need for contraception counseling for patients with SCD and provide recommendations for hormonal contraceptives in women • To describe fertility preservation options for children and adults with SCD considering stem cell transplantation

show abstract

Section: Unplanned Pregnancy and Scdmentioning

confidence: 99%

Reproductive issues in sickle cell disease

Smith‐Whitley

2014

Hematology

View full text Add to dashboard Cite

show abstract

“…SCD is considered a "prothrombotic" state because of abnormal RBC rheology, hyperviscosity, endothelial dysfunction, and red cells adhesion; 64,65 increased platelet activation; venous sludging and abnormal coagulation associated with increased thrombotic complications in patients receiving estrogens. 66 Moreover, VTE, defined as deep vein thrombosis (DVT) or pulmonary embolism (PE), is a frequent and severe clinical complication in adults with SCD, and is likely, at least in part, to be the result of this hypercoagulable state. Up to 12% of patients with SCD have a VTE by 40 years of age.…”

Section: Medical Eligibility Contraception (Mec)mentioning

confidence: 99%

Current Issues and Options for Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease: An Update for Health Care Professionals

Sanctis¹,

Soliman

Daar

et al. 2020

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Abstract. Women with sickle cell disease (SCD) are of particular concern due to the significantly increased risk of pregnancy-related morbidity, mortality, and adverse outcomes. They have limited knowledge of the risks of pregnancy and childbirth as well as of the benefits and risks from the use of contraceptives. Thus, there is urgent need for appropriate information about reproductive family planning to reduce unintended pregnancy. Any decision regarding the use of contraceptives has to be based on the efficacy and the risks and benefits of the method used. Both the World Health Organization (WHO) and the Center for Disease Control and Prevention (CDC) have developed, published, and updated evidence-based guidelines for medical providers for the use of contraceptives in patients with specific medical chronic conditions. This article provides an overview of the present knowledge for the use of contraceptives in women with SCD. We believe that the collaboration between health care professionals (hematologists, obstetricians, endocrinologists, and primary care providers) can play a major role in identifying the safer contraceptive method to abolish the risks of unintended pregnancy and preserve the health status of patients with SCD.

show abstract

“…20 The risk of infection with intrauterine contraceptive devices should be noted, but this in itself is not a contraindication to their use if this is the woman's preference.…”

Section: Contraceptionmentioning

confidence: 99%

Haemoglobinopathies in pregnancy

Johnston

2005

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

The haemoglobinopathies are a complex group of red blood cell disorders. The ethnic diversity of the population in many parts of the UK means that these disorders are increasingly being seen in the antenatal setting. With the planned introduction of both antenatal and newborn screening programmes for haemoglobinopathies in England and Wales, a review of the subject is timely. This article explains the genetic background and clinical features of the major haemoglobinopathies, discusses antenatal screening and prenatal diagnosis, and highlights the implications of pregnancy for women with these disorders.

show abstract

Sickle Cell Diseases and Hormonal Contraception

Cited by 18 publications

References 31 publications

Reproductive issues in sickle cell disease

Reproductive issues in sickle cell disease

Current Issues and Options for Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease: An Update for Health Care Professionals

Haemoglobinopathies in pregnancy

Contact Info

Product

Resources

About